Tradename | Company | Number | Date | Products |
---|---|---|---|---|
CONTRAVE | Nalpropion Pharmaceuticals | N-200063 RX | 2014-09-10 | 1 products, RLD, RS |
Brand Name | Status | Last Update |
---|---|---|
contrave | New Drug Application | 2025-05-07 |
naltrexone | unapproved drug other | 2018-03-19 |
naltrexone hydrochloride | ANDA | 2025-05-21 |
naltrexone hyrdochloride | ANDA | 2009-07-21 |
trexall | ANDA | 2021-04-30 |
vivitrol | New Drug Application | 2024-05-22 |
Patent | Expires | Flag | FDA Information |
---|---|---|---|
Bupropion Hydrochloride / Naltrexone Hydrochloride, Contrave, Nalpropion | |||
10231964 | 2034-07-02 | U-1583 | |
10828294 | 2034-07-02 | U-1583 | |
10835527 | 2034-07-02 | U-1583 | |
9633575 | 2033-06-25 | U-1583 | |
10403170 | 2033-06-05 | U-1583 | |
11139056 | 2033-06-05 | U-1583 | |
9248123 | 2032-01-13 | U-1808 | |
11033543 | 2031-01-10 | U-1583 | |
8916195 | 2030-02-02 | U-1639 | |
11324741 | 2029-05-29 | U-1583 | |
8088786 | 2029-02-03 | DP | |
8318788 | 2027-11-08 | U-1584 | |
8722085 | 2027-11-08 | U-1585 | |
9125868 | 2027-11-08 | U-1585 | |
10307376 | 2027-11-08 | U-1585 | |
9107837 | 2027-06-04 | U-1639 | |
7375111 | 2025-03-26 | DP | |
7462626 | 2024-07-20 | U-1583 | |
8815889 | 2024-07-20 | U-1586 | |
11278544 | 2024-04-21 | U-1583 | |
Morphine Sulfate / Naltrexone Hydrochloride, Embeda, Alpharma Pharms | |||
8623418 | 2029-11-07 | U-1640 | |
7815934 | 2027-12-12 | DP | |
7682633 | 2027-06-19 | U-1510 | |
7682634 | 2027-06-19 | DP | |
8158156 | 2027-06-19 | U-1510 | |
8846104 | 2027-06-19 | DP | |
8877247 | 2027-06-19 | DP | |
8685443 | 2025-07-03 | U-1508 | |
8685444 | 2025-07-03 | DP | |
Naltrexone, Vivitrol, Alkermes | |||
7919499 | 2029-10-15 | U-1123, U-1124 |
Code | Description |
---|---|
G2073 | Medication assisted treatment, naltrexone; weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if performed (provision of the services by a medicare-enrolled opioid treatment program) |
J2212 | Injection, methylnaltrexone, 0.1 mg |
J2315 | Injection, naltrexone, depot form, 1 mg |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Alcoholism | D000437 | EFO_0003829 | F10.1 | 13 | 31 | 24 | 47 | 12 | 122 |
Opioid-related disorders | D009293 | EFO_0005611 | F11 | 16 | 46 | 32 | 10 | 30 | 115 |
Obesity | D009765 | EFO_0001073 | E66.9 | 1 | 11 | 14 | 16 | 7 | 42 |
Substance-related disorders | D019966 | EFO_0003890 | F13 | 2 | 16 | 7 | 4 | 11 | 34 |
Alcohol drinking | D000428 | EFO_0004329 | — | 7 | 11 | 5 | 10 | 4 | 32 |
Healthy volunteers/patients | — | — | — | 22 | 2 | — | 2 | 1 | 26 |
Depression | D003863 | — | F33.9 | 4 | 4 | 4 | 6 | 1 | 18 |
Overweight | D050177 | — | E66.3 | — | 7 | 9 | 2 | 2 | 17 |
Hiv infections | D015658 | EFO_0000764 | B20 | 2 | 8 | 3 | 3 | 3 | 15 |
Depressive disorder | D003866 | EFO_1002014 | F32.A | 4 | 4 | 3 | 5 | — | 15 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Cocaine-related disorders | D019970 | — | F14 | 2 | 11 | 4 | — | 2 | 17 |
Recurrence | D012008 | — | — | 1 | 5 | 3 | — | 2 | 9 |
Bulimia | D002032 | — | F50.2 | 2 | 6 | 6 | — | 1 | 9 |
Addictive behavior | D016739 | EFO_0004347 | — | 1 | 4 | 1 | — | 1 | 6 |
Migraine disorders | D008881 | EFO_0003821 | G43 | — | 5 | 1 | — | 1 | 6 |
Binge-eating disorder | D056912 | — | F50.2 | — | 5 | 5 | — | 1 | 6 |
Analgesia | D000698 | — | — | 3 | — | 1 | — | — | 4 |
Low back pain | D017116 | — | M54.5 | — | 2 | 1 | — | — | 3 |
Back pain | D001416 | — | M54 | — | 2 | 1 | — | — | 3 |
Nerve compression syndromes | D009408 | — | — | — | — | 3 | — | — | 3 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Covid-19 | D000086382 | — | U07.1 | 1 | 4 | — | — | — | 5 |
Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 3 | — | — | 1 | 4 |
Marijuana abuse | D002189 | EFO_0007191 | F12 | 1 | 4 | — | — | — | 4 |
Weight gain | D015430 | — | — | 2 | 2 | — | — | 1 | 3 |
Fatigue | D005221 | — | R53.83 | — | 2 | — | — | 1 | 3 |
Atopic dermatitis | D003876 | EFO_0000274 | L20 | 1 | 2 | — | — | — | 3 |
Eczema | D004485 | — | L30.9 | 1 | 2 | — | — | — | 3 |
Dermatitis | D003872 | — | L30.9 | 1 | 2 | — | — | — | 3 |
Chronic fatigue syndrome | D015673 | EFO_0004540 | G93.31 | — | 2 | — | — | 1 | 3 |
Crohn disease | D003424 | EFO_0000384 | K50 | — | 3 | — | — | — | 3 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Pharmacokinetics | D010599 | — | — | 4 | — | — | — | — | 4 |
Biological availability | D001682 | — | — | 2 | — | — | — | 1 | 3 |
Treatment-resistant depressive disorder | D061218 | — | — | 2 | — | — | — | 1 | 3 |
Pain management | D059408 | — | — | 1 | — | — | — | — | 1 |
Cognition | D003071 | EFO_0003925 | — | 1 | — | — | — | — | 1 |
Postoperative pain | D010149 | — | G89.18 | 1 | — | — | — | — | 1 |
Narcotic-related disorders | D000079524 | — | — | 1 | — | — | — | — | 1 |
Intestinal obstruction | D007415 | — | K56.60 | 1 | — | — | — | — | 1 |
Renal insufficiency | D051437 | — | N19 | 1 | — | — | — | — | 1 |
Psoriasis | D011565 | EFO_0000676 | L40 | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Disease | D004194 | EFO_0000408 | R69 | — | — | — | — | 1 | 1 |
Neonatal abstinence syndrome | D009357 | EFO_0005799 | P96.1 | — | — | — | — | 1 | 1 |
High-risk pregnancy | D018566 | — | — | — | — | — | — | 1 | 1 |
Self concept | D012649 | — | — | — | — | — | — | 1 | 1 |
Psychological distance | D012929 | — | — | — | — | — | — | 1 | 1 |
Social psychology | D011593 | — | — | — | — | — | — | 1 | 1 |
Temporomandibular joint disorders | D013705 | — | M26.6 | — | — | — | — | 1 | 1 |
Facial pain | D005157 | — | R51.9 | — | — | — | — | 1 | 1 |
Temporomandibular joint dysfunction syndrome | D013706 | — | — | — | — | — | — | 1 | 1 |
Tuberculosis | D014376 | EFO_0000774 | A15-A19 | — | — | — | — | 1 | 1 |
Drug common name | Naltrexone |
INN | naltrexone |
Description | Naltrexone is an organic heteropentacyclic compound that is naloxone substituted in which the allyl group attached to the nitrogen is replaced by a cyclopropylmethyl group. A mu-opioid receptor antagonist, it is used to treat alcohol dependence. It has a role as a mu-opioid receptor antagonist, a central nervous system depressant, an environmental contaminant, a xenobiotic and an antidote to opioid poisoning. It is an organic heteropentacyclic compound, a morphinane-like compound and a member of cyclopropanes. It is a conjugate base of a naltrexone(1+). |
Classification | Small molecule |
Drug class | narcotic agonists/antagonists (normorphine type) |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5 |
PDB | — |
CAS-ID | 16590-41-3 |
RxCUI | — |
ChEMBL ID | CHEMBL19019 |
ChEBI ID | 7465 |
PubChem CID | 5360515 |
DrugBank | DB00704 |
UNII ID | 5S6W795CQM (ChemIDplus, GSRS) |